

In the Claims

1. (Currently amended) A pharmaceutical composition comprising ~~two or more~~ at least one therapeutic agents selected from the group consisting of:
 - (a) azo-bonded 4-APAA compound;
 - (b) non-azo bonded 4-APAA compound;
 - (c) azo-bonded 5-ASA compound;
 - (d) non-azo bonded 5-ASA compound; andat least one therapeutic agent selected from the group consisting of:
 - (e) 4-APAA compound azo bonded to a 5-ASA compound; and
 - a combination of 4-APAA compound and a 5-ASA compound.

2. (Currently amended) The pharmaceutical composition of claim 1 further comprising another a ~~third~~ therapeutic agent selected from the group consisting of: steroids, antibiotics, stool softeners, stool hardeners, nutraceuticals, probiotic agents and organisms, and nicotinic agents.

3. (Original) The pharmaceutical composition of claim 1 formulated to deliver the therapeutic agents to the small intestine and/or the colon.

4. (Original) The pharmaceutical composition of claim 1 formulated to release the therapeutic agents along the length of the small intestine and the colon.

5. (Original) The pharmaceutical composition of claim 1 formulated to release the therapeutic agents along the length of the distal portion of the small intestine and the colon.

6. (Original) The pharmaceutical composition of claim 1 formulated to release the therapeutic agents along the length of the colon.

7. (Original) The pharmaceutical composition of claim 1 formulated to pass through the stomach and to release the active agent in the intestine.

8. (Currently amended) The pharmaceutical composition of claim ~~4~~ 6 formulated as a suppository.

9. (Currently amended) The pharmaceutical composition of claim 4 ~~6~~ formulated for administration as an enema.

10-14. (Cancelled)

15. (Currently amended) ~~A~~ The pharmaceutical composition comprising at least two therapeutic agents selected from the group consisting of:

azo-bonded 4-APAA compound;

non-azo bonded 4-APAA compound;

azo-bonded 5-ASA compound;

non-azo bonded 5-ASA compound;

4-APAA compound azo bonded to a 5-ASA compound; and

a combination of 4-APAA compound and a 5-ASA compound,

wherein the composition is ~~of claim 1~~ formulated to release:

(a) at least one component selected from the group consisting of a first and a second component, wherein the (i)-a first component comprising one or more of the therapeutic agents formulated for release in the stomach, and the (ii)-a second component comprising one or more of the therapeutic agents formulated for release in the small intestine or distal portion of the small intestine, wherein the therapeutic agents for the distal portion of the small intestine is a 4-APAA compound azo bonded to a 5-ASA compound or a combination of 4-APAA and 5-ASA compounds;

and

(b) a third component comprising one or more of the therapeutic agents formulated for release in the colon.

16. (Currently amended) The pharmaceutical composition of claim 15 wherein:

~~(a)~~the first component comprises a 5-ASA compound; ~~(b)~~ the second component comprises a 5-ASA compound and a 4-APAA compound formulated for release in a distal portion of the small intestine; and ~~(c)~~the third component comprises a combination of a 5-ASA compound and a 4-APAA compound or 4-APAA compound azo bonded to a 5-ASA compound.

17. (Currently amended) The pharmaceutical composition of claim 15 wherein:

~~(a)~~ the first component comprises a 5-ASA compound;

~~(b)~~ the second component comprises:

- (~~ii~~) a 5-ASA compound formulated for release in the small intestine; and
- (~~iii~~) a 5-ASA compound and a 4-APAA compound formulated for release in a distal portion of the small intestine; and
- (~~e~~) the third component comprises a combination of a 5-ASA compound and a 4-APAA compound or 4-APAA compound azo bonded to a 5-ASA compound.
18. (Currently amended) The pharmaceutical composition of claim 15 wherein:
- (~~a~~) the first component comprises a 5-ASA compound;
- (~~b~~) the second component is not present; and
- (~~e~~) the third component comprises a combination of a 5-ASA compound and a 4-APAA compound or 4-APAA compound azo bonded to a 5-ASA compound.
19. (Currently amended) The pharmaceutical composition of claim 15 wherein:
- (~~a~~) the first component comprises a 5-ASA compound;
- (~~b~~) the second component comprises a 5-ASA compound formulated for release in the small intestine; and
- (~~e~~) the third component comprises a combination of a 5-ASA compound and a 4-APAA compound or 4-APAA compound azo bonded to a 5-ASA compound.
20. (Currently amended) The pharmaceutical composition of claim 15 wherein:
- (~~a~~) the first component comprises a 4-APAA compound;
- (~~b~~) the second component comprises a 5-ASA compound and a 4-APAA compound formulated for release in a distal portion of the small intestine; and
- (~~e~~) the third component comprises a combination of a 5-ASA compound and a 4-APAA compound or 4-APAA compound azo bonded to a 5-ASA compound.
21. (Currently amended) The pharmaceutical composition of claim 15 wherein:
- (~~a~~) the first component comprises a 4-APAA compound;
- (~~b~~) the second component comprises:
- (~~i~~) a 4-APAA compound formulated for release in the small intestine; and
- (~~ii~~) a 5-ASA compound and 4-APAA compound formulated for release in a distal portion of the small intestine; and
- (~~e~~) the third component comprises a combination of a 5-ASA compound and a 4-APAA compound or 4-APAA compound azo bonded to a 5-ASA compound.

22. (Currently amended) The pharmaceutical composition of claim 15 wherein:
- ~~(a)~~ the first component comprises a 4-APAA compound;
 - ~~(b)~~ the second component is not present; and
 - ~~(c)~~ the third component comprises a combination of a 5-ASA compound and a 4-APAA compound or 4-APAA compound azo bonded to a 5-ASA compound.
23. (Currently amended) The pharmaceutical composition of claim 15 wherein:
- ~~(a)~~ the first component comprises a 4-APAA compound;
 - ~~(b)~~ the second component comprises a 4-APAA compound formulated for release in the small intestine; and
 - ~~(c)~~ the third component comprises a combination of a 5-ASA compound and a 4-APAA compound or 4-APAA compound azo bonded to a 5-ASA compound.
24. (Currently amended) The pharmaceutical composition of claim 15 wherein:
- ~~(a)~~ the first component is not present;
 - ~~(b)~~ the second component comprises a 5-ASA compound and 4-APAA compound formulated for release in a distal portion of the small intestine; and
 - ~~(c)~~ the third component comprises a combination of a 5-ASA compound and a 4-APAA compound or 4-APAA compound azo bonded to a 5-ASA compound.
25. (Currently amended) The pharmaceutical composition of claim 15 wherein:
- ~~(a)~~ the first component is not present;
 - ~~(b)~~ the second component comprises:
 - ~~(i)~~ a 5-ASA compound formulated for release in the small intestine; and
 - ~~(ii)~~ a 5-ASA compound and 4-APAA compound formulated for release in a distal portion of the small intestine; and
 - ~~(c)~~ the third component comprises a combination of a 5-ASA compound and a 4-APAA compound or 4-APAA compound azo bonded to a 5-ASA compound.
26. (Currently amended) The pharmaceutical composition of claim 15 wherein:
- ~~(a)~~ the first component is not present;
 - ~~(b)~~ the second component comprises a 5-ASA compound formulated for release in the small intestine; and

~~(e)~~ the third component comprises a combination of a 5-ASA compound and a 4-APAA compound or 4-APAA compound azo bonded to a 5-ASA compound.

27. (Currently amended) The pharmaceutical composition of claim 15 wherein:

~~(a)~~ the first component is not present;

~~(b)~~ the second component comprises a 5-ASA compound and 4-APAA compound formulated for release in a distal portion of the small intestine; and

~~(e)~~ the third component comprises a combination of a 5-ASA compound and a 4-APAA compound or 4-APAA compound azo bonded to a 5-ASA compound.

28. (Currently amended) The pharmaceutical composition of claim 15 wherein:

~~(a)~~ the first component is not present;

~~(b)~~ the second component comprises:

~~(i)~~ a 4-APAA compound formulated for release in the small intestine; and

~~(b)~~ a 5-ASA compound and 4-APAA compound formulated for release in a distal portion of the small intestine; and

~~(e)~~ the third component comprises a combination of a 5-ASA compound and a 4-APAA compound or 4-APAA compound azo bonded to a 5-ASA compound.

29. (Currently amended) The pharmaceutical composition of claim 15 wherein:

~~(a)~~ the first component is not present;

~~(b)~~ the second component comprises a 4-APAA compound formulated for release in the small intestine; and

~~(e)~~ the third component comprises a combination of a 5-ASA compound and a 4-APAA compound or 4-APAA compound azo bonded to a 5-ASA compound.

30. (Currently amended) A method of treating an inflammatory colon condition comprising administering to a subject a pharmaceutical composition of claim 1,2, 3, 4, 5, 6, 7, 8, 9, ~~10, 11, 12, 13, 14,~~ 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, ~~29~~ or 32 in an amount sufficient to reduce the inflammatory gastrointestinal condition.

31. (Cancelled).

32. (New) The pharmaceutical composition of claim 15, wherein the third component is a 4-APAA compound azo bonded to a 5-ASA compound.